A Phase 3 study of S-217622 in pediatric participants aged 6 to <12 with SARS-CoV-2 infection
Latest Information Update: 10 Oct 2024
Price :
$35 *
At a glance
- Drugs Ensitrelvir (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Shionogi
- 02 Feb 2024 New trial record
- 29 Jun 2023 According to a Shionogi media release, the first patient has been enrolled in this study.